Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
暂无分享,去创建一个
Pedro Mendez | Jose Luis Mate | Rafael Rosell | J. Mate | Y. Ichinose | R. Rosell | M. Taron | N. Reguart | B. Cirauqui | J. Sánchez | B. Besse | P. Méndez | C. Sarries | C. Queralt | K. Nishiyama | J. Sánchez | T. Morán | Benjamin Besse | Teresa Moran | Noemi Reguart | Yukito Ichinose | Miquel Taron | Carme Sarries | Cristina Queralt | Jose Miguel Sanchez | Ken-Ichi Nishiyama | Beatriz Cirauqui | Maria Perez | Jose Javier Sanchez | M. Pérez
[1] S. Steinberg,et al. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.
[2] L. V. van't Veer,et al. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Joe W. Gray,et al. PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.
[4] W. Alvord,et al. Ras Oncogene-Induced Sensitization to 1-β-d-Arabinofuranosylcytosine , 1999 .
[5] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[6] M. Spitz,et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. , 2000, Journal of the National Cancer Institute.
[7] R. Simon,et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. , 2000, Cancer research.
[8] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[9] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[10] M. Sliwkowski,et al. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.
[11] G. Mills,et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors , 2003, Oncogene.
[12] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[14] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[15] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[16] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[17] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[18] Roy S Herbst,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] G. Giaccone,et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Daniel A. Haber,et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.
[21] M. Kuwano,et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. , 2004, Molecular cancer therapeutics.
[22] T. Crook,et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo , 2004, Oncogene.
[23] J. Dancey. Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow. , 2004, Cancer cell.
[24] C. Harris,et al. Tobacco Carcinogen-Induced Cellular Transformation Increases Activation of the Phosphatidylinositol 3′-Kinase/Akt Pathway in Vitro and in Vivo , 2004, Cancer Research.
[25] William Pao,et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.